公开(公告)号：US12109346B2

公开(公告)日：2024-10-08

申请号：US16988679

申请日：2020-08-09

申请人： ELIAZ THERAPEUTICS, INC

发明人： Isaac Eliaz

IPC分类号： A61M1/36 ,  A61K35/14 ,  A61K35/16 ,  A61K35/17 ,  A61K39/395 ,  A61M1/34 ,  A61N5/06

CPC分类号： A61M1/362 ,  A61K35/14 ,  A61K35/16 ,  A61K35/17 ,  A61K39/3955 ,  A61M1/3496 ,  A61M1/3683 ,  A61N5/062

摘要： A system and method for the practice of apheresis employs modules in the system which can be selected for a particular patient to treat particular situations or combinations of difficulties. In one example, Gal-3 mediates a large number of body reactions, and is an effective protector of tumor microenvironments and the like, as well inflammation driver. Removal of Gal-3 may make antic-cancer treatments, like photopheresis and TNF administration more effective. Separate modules, such as one for photopheresis and one for TNF receptor removal, may be combined with a module for the reduction of Gal-3, to render the combination of treatments each more effective than if administered alone.

公开(公告)号：US11883575B2

公开(公告)日：2024-01-30

申请号：US16576484

申请日：2019-09-19

申请人： Fenwal, Inc.

发明人： Christopher J. Wegener ,  Bret M. Olson ,  Alaina Schlinker ,  Steven Binninger ,  Avnie A. Kadakia ,  Kyle Thompson ,  Kyle Wolok ,  Melanie Hamilton

IPC分类号： A61M1/26 ,  A61M1/36 ,  C12M1/00 ,  C12M1/26 ,  C12M1/36 ,  G01N33/543

CPC分类号： A61M1/262 ,  A61M1/265 ,  A61M1/362 ,  A61M1/3618 ,  C12M23/28 ,  C12M29/14 ,  C12M33/14 ,  C12M41/48 ,  C12M47/04 ,  G01N33/54326 ,  G01N33/54366

摘要： A cell processing system includes at least one processor connectable to a source container filled with a biological fluid, the processor including a spinning membrane configured to receive and separate target cells from the biological fluid, the target cells exiting at a first outlet, first and second containers selectively connected to the first outlet; and a magnet. The system also includes a controller configured to operate the spinning membrane to receive biological fluid and to direct the target cells to the first container, to pause to permit magnetic particles to be associated with the target cells in the first container, to operate the spinning membrane to receive the contents of the first container with the magnet applied to the target cells associated with the magnetic particles, to remove or deactivate the magnet, and to transfer the target cells to the second container.

公开(公告)号：US11806459B2

公开(公告)日：2023-11-07

申请号：US17006875

申请日：2021-01-16

申请人： Henry J. Smith

发明人： Henry J. Smith

IPC分类号： A61M1/36 ,  A61M1/34 ,  A61K31/727 ,  A61P9/12 ,  G01N33/68 ,  B01D61/14 ,  B01D69/02 ,  B01D15/38

CPC分类号： A61M1/362 ,  A61K31/727 ,  A61M1/3496 ,  A61P9/12 ,  B01D15/3809 ,  B01D61/145 ,  B01D69/02 ,  G01N33/689 ,  A61M2202/07 ,  G01N2333/475 ,  G01N2800/368 ,  G01N2800/56

摘要： This invention teaches a targeted apheresis method of treating a pregnant woman with preeclampsia, or who is predisposed to developing preeclampsia, utilizing immobilized binding agents contained within an apheresis device to remove sVEGFR-1 and sVEGFR-2, and one or more other harmful factors associated with preeclampsia selected from a list that includes: sEndoglin, Endothelin-1, TNF, IL-1, IL-6, IL-12, IL-18, digitalis-like factor, ouabain-like factor, marinobufagenin, .marinobufotoxenin, and telocinobufagin. The binding agents used are antibodies or aptamers or binding peptides. Reducing the concentration of sVEGFR-1, sVEGFR-2 and other harmful factors in the pregnant woman's blood using targeted apheresis will alleviate or delay the symptoms of preeclampsia, and thus postpone premature delivery of the baby so that the baby is born at term or as close to term as possible.

公开(公告)号：US11660383B2

公开(公告)日：2023-05-30

申请号：US17113726

申请日：2020-12-07

申请人： TORAY INDUSTRIES, INC.

发明人： Naotoshi Tomita ,  Kaoru Shimada ,  Hiroshi Takahashi

IPC分类号： A61M1/36 ,  B01J20/26 ,  B01J20/28 ,  B01D15/38 ,  B01J20/288

CPC分类号： A61M1/3679 ,  A61M1/362 ,  B01D15/3823 ,  B01J20/265 ,  B01J20/28 ,  B01J20/288 ,  B01J20/28023 ,  B01J20/28054 ,  A61M2202/0057 ,  A61M2202/0427 ,  A61M2202/0439 ,  A61M2202/0447 ,  A61M2202/07 ,  B01J2220/50

摘要： An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

公开(公告)号：US20180256806A1

公开(公告)日：2018-09-13

申请号：US15974881

申请日：2018-05-09

申请人： Mallinckrodt Hospital Products IP Limited

发明人： David Peritt ,  Philip Wong ,  Janet Lesley Macpherson ,  Kevin Henrichsen ,  Geoffrey Phillip Symonds ,  Susan Pond

IPC分类号： A61M1/34 ,  B04B11/02 ,  A61M1/38 ,  B04B5/10 ,  A61M1/36 ,  B03C1/015

CPC分类号： A61M1/3496 ,  A61M1/362 ,  A61M1/3626 ,  A61M1/3672 ,  A61M1/3689 ,  A61M1/3696 ,  A61M1/38 ,  A61M2202/0064 ,  A61M2202/0439 ,  B03C1/015 ,  B04B5/10 ,  B04B11/02

摘要： Methods (300), devices, and systems of processing blood are described. The method (300) comprises the steps of: obtaining (312) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collecting (314) bulk mononuclear blood cells from the blood by leukapheresis implemented using the blood processing device in the closed loop; and enriching (316) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.

公开(公告)号：US20180169319A1

公开(公告)日：2018-06-21

申请号：US15786883

申请日：2017-10-18

申请人： Marv Enterprises, LLC

发明人： Mitchell S. Felder

IPC分类号： A61M1/36 ,  C07K16/30 ,  C07K16/22 ,  C07K16/00 ,  C07K16/18

CPC分类号： A61M1/362 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/30 ,  C07K2319/31

摘要： The present invention relates to the treatment of cancers. Specifically, the invention pertains to a method for the extracorporeal treatment of one or more body fluids (e.g., blood or cerebrospinal fluid, CSF) in two stages characterized by removing a body fluid (e.g., blood or CSF) from a living body diseased with a type of cancer, passing the body fluid through a first stage of applying a treatment to at least one antigen in the body fluid. More specifically, the treatment comprises creating an antibody-antigen moiety during passage thereof through said first stage, passing the treated body fluid through a second stage, removing antibody-antigen moiety from the body fluid during passage through the second stage, and returning the purified body fluid to the body.

公开(公告)号：US20180169273A1

公开(公告)日：2018-06-21

申请号：US15843803

申请日：2017-12-15

申请人： uniQure IP B.V.

发明人： Valerie Ferreira

IPC分类号： A61K48/00 ,  C12N7/00 ,  A61K9/00

CPC分类号： A61K48/0083 ,  A61K9/0019 ,  A61K48/0075 ,  A61M1/3486 ,  A61M1/362 ,  A61M1/3679 ,  A61M5/14 ,  A61M2202/0417 ,  C12N7/00 ,  C12N15/86 ,  C12N2750/14143

摘要： Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.

公开(公告)号：US09833475B2

公开(公告)日：2017-12-05

申请号：US14970574

申请日：2015-12-16

申请人： ARTHREX, INC.

发明人： Christopher M. Bare ,  Brandon L. Roller ,  Melissa S. Tucker

IPC分类号： A61K38/00 ,  A61K35/16 ,  A61K38/17 ,  A61M1/36 ,  C07K16/24 ,  A61J1/20

CPC分类号： A61K35/16 ,  A61J1/2089 ,  A61K38/1793 ,  A61M1/362 ,  C07K16/245

摘要： Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1β, IL-α, IL-6, TNFα, IFNγ and MMPS as these proteins inhibit the healing process.

公开(公告)号：US20170065717A1

公开(公告)日：2017-03-09

申请号：US15305342

申请日：2015-04-14

申请人： Marv Enterprises, LLC

发明人： Mitchell S. Felder

IPC分类号： A61K39/395 ,  A61M1/36 ,  C07K16/22 ,  G01N33/68 ,  A61K9/00 ,  C07K16/24

CPC分类号： A61K39/3955 ,  A61K9/0019 ,  A61K35/14 ,  A61K35/30 ,  A61M1/362 ,  B01D15/34 ,  B01D15/3804 ,  C07K16/22 ,  C07K16/24 ,  C07K16/241 ,  C07K16/244 ,  C07K16/248 ,  C07K2317/72 ,  G01N33/6896 ,  G01N2333/495 ,  G01N2333/523 ,  G01N2333/525 ,  G01N2333/54 ,  G01N2333/5412 ,  G01N2800/2878 ,  G01N2800/52

摘要： A method for treating muscular dystrophy is described, including extracorporeally treating a patient's bodily fluid. The bodily fluid is removed from a patient before treatment and returned to the patient after treatment. The treatment targets an antigen associated with muscular dystrophy, such as interleukin-17 (IL-17), TNF-α (tumor necrosis factor-alpha), interleukin-6 (IL-6), CTGF-β (transforming growth factor-beta), MCP-1 (monocyte chemotactic protein-1), and combinations thereof. The treatment removes the antigen from the bodily fluid. Preferably, the treatment is removed from the bodily fluid before returning to the patient.

摘要翻译： 描述了一种治疗肌营养不良的方法，包括体外治疗患者的体液。 在治疗前从患者身上取出体液，并在治疗后返回给患者。 该治疗针对与肌营养不良相关的抗原，如白介素17（IL-17），TNF-α（肿瘤坏死因子-α），白细胞介素-6（IL-6），CTGF-β（转化生长因子-β ），MCP-1（单核细胞趋化蛋白-1）及其组合。 该处理从体液中除去抗原。 优选地，在返回到患者之前，将该处理从体液中除去。

公开(公告)号：US20160331886A1

公开(公告)日：2016-11-17

申请号：US15199737

申请日：2016-06-30

申请人： EXTHERA MEDICAL CORPORATION

发明人： ROBERT S. WARD ,  Keith R. McCrea ,  Olle Larm ,  Lars Adolfsson

IPC分类号： A61M1/36 ,  A61M1/38

CPC分类号： A61M1/362 ,  A61K31/60 ,  A61K31/722 ,  A61K31/727 ,  A61K31/728 ,  A61M1/3472 ,  A61M1/3496 ,  A61M1/36 ,  A61M1/3621 ,  A61M1/3673 ,  A61M1/3679 ,  A61M1/3687 ,  A61M1/38 ,  A61M2202/0057

摘要： The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

摘要翻译： 本发明涉及通过使血液与已经用肝素，硫酸乙酰肝素和/或表面处理的固体，基本上非微孔的底物接触，从血液或血清（血液）中除去细胞因子和/或病原体的方法 对待除去的细胞因子或病原体（吸附物）具有结合亲和力的其它分子或化学基团（吸附介质或介质），并且其中所述介质中的间质通道的大小与介质的量平衡 表面积和培养基上结合位点的表面浓度，以提供足够的吸附能力，同时还允许血液通过吸附介质的相对较高的流速。